PMID- 12858355
OWN - NLM
STAT- MEDLINE
DCOM- 20030916
LR  - 20220330
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 56
IP  - 4
DP  - 2003 Sep 1
TI  - Identification of an HLA-A*0201-restricted T-cell epitope derived from the 
      prostate cancer-associated protein trp-p8.
PG  - 270-9
AB  - BACKGROUND: New concepts for the immunotherapy of prostate carcinoma (PCa) 
      largely depend on the identification of suitable target antigens that are present 
      in a high percentage of prostate tumors. Their expression in normal tissues 
      should be restricted to the prostate and they should be immunogenic in vivo. The 
      number of antigens displaying these properties is still limited. Here, we 
      identify for the first time an immunogenic peptide derived from the 
      prostate-specific protein transient receptor potential-p8 (trp-p8) that is 
      recognized by cytotoxic T lymphocytes (CTLs) from PCa patients. METHODS: To 
      determine the abundance of trp-p8 in prostate tumors, the expression level of 
      trp-p8 mRNA was quantitatively analyzed in a panel of prostate cancer tissues. 
      Trp-p8-derived human leukocyte antigen (HLA)-A*0201-restricted peptides were 
      selected and tested for the in vitro activation of CTLs when loaded on autologous 
      dendritic cells (DCs). RESULTS: Trp-p8 mRNA was found to be expressed in all 
      prostate tumors and in the corresponding normal prostate tissue. Of five selected 
      trp-p8-derived peptides, only peptide GLMKYIGEV was shown to activate specific 
      CTLs, which effectively lysed PCa cells confirming the endogenous generation and 
      presentation of this peptide by tumor cells. CONCLUSIONS: Our results suggest 
      this antigen as a suitable target for the T-cell-based immunotherapy of PCa.
CI  - Copyright 2003 Wiley-Liss, Inc.
FAU - Kiessling, Andrea
AU  - Kiessling A
AD  - Institute of Immunology, Medical Faculty, Technical University of Dresden, 
      Dresden, Germany.
FAU - Fussel, Susanne
AU  - Fussel S
FAU - Schmitz, Marc
AU  - Schmitz M
FAU - Stevanovic, Stefan
AU  - Stevanovic S
FAU - Meye, Axel
AU  - Meye A
FAU - Weigle, Bernd
AU  - Weigle B
FAU - Klenk, Ulrich
AU  - Klenk U
FAU - Wirth, Manfred P
AU  - Wirth MP
FAU - Rieber, Ernst P
AU  - Rieber EP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Ion Channels)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 0 (RNA, Messenger)
RN  - 0 (TRPM Cation Channels)
RN  - 0 (TRPM8 protein, human)
SB  - IM
MH  - Antigens, Neoplasm/*immunology
MH  - Dendritic Cells
MH  - Gene Expression Regulation, Neoplastic
MH  - HLA-A Antigens/*immunology
MH  - HLA-A2 Antigen
MH  - Humans
MH  - Immunotherapy
MH  - Ion Channels/*biosynthesis/*immunology
MH  - Male
MH  - Neoplasm Proteins/*biosynthesis/*immunology
MH  - Peptides
MH  - Polymerase Chain Reaction
MH  - Prostatic Neoplasms/*immunology/*pathology
MH  - RNA, Messenger/analysis
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - TRPM Cation Channels
EDAT- 2003/07/15 05:00
MHDA- 2003/09/17 05:00
CRDT- 2003/07/15 05:00
PHST- 2003/07/15 05:00 [pubmed]
PHST- 2003/09/17 05:00 [medline]
PHST- 2003/07/15 05:00 [entrez]
AID - 10.1002/pros.10265 [doi]
PST - ppublish
SO  - Prostate. 2003 Sep 1;56(4):270-9. doi: 10.1002/pros.10265.